CXCL9 and melanoma: When comparing Arms A and B, we found upregulation of IL1R in Arm A, which has been shown to both maintain immunosuppressive TAM phenotypes and promote tumor growth via upregulation of PD1 in melanoma,61 while CXCL9 and CXCL10, both ligands for CXCR3, were upregulated in Arm B, for which expression in TAMs is associated with effector CD8+ T cell infiltration into various solid tumors and are markers of response to ICIs.62